Truist Financial Corp Buys 1,715 Shares of Castle Biosciences, Inc. $CSTL

Truist Financial Corp grew its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) by 7.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 24,023 shares of the company’s stock after acquiring an additional 1,715 shares during the period. Truist Financial Corp owned about 0.08% of Castle Biosciences worth $491,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of CSTL. Harbour Investments Inc. bought a new stake in shares of Castle Biosciences during the first quarter valued at approximately $50,000. Jones Financial Companies Lllp raised its stake in shares of Castle Biosciences by 10,592.0% during the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after acquiring an additional 2,648 shares in the last quarter. Amundi raised its stake in Castle Biosciences by 15,811.5% in the first quarter. Amundi now owns 4,137 shares of the company’s stock worth $79,000 after buying an additional 4,111 shares in the last quarter. CWM LLC raised its stake in Castle Biosciences by 835.0% in the first quarter. CWM LLC now owns 4,142 shares of the company’s stock worth $83,000 after buying an additional 3,699 shares in the last quarter. Finally, GAMMA Investing LLC raised its stake in Castle Biosciences by 1,865.8% in the first quarter. GAMMA Investing LLC now owns 4,364 shares of the company’s stock worth $87,000 after buying an additional 4,142 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Insider Buying and Selling at Castle Biosciences

In other Castle Biosciences news, insider Derek J. Maetzold sold 1,339 shares of the company’s stock in a transaction dated Wednesday, September 17th. The shares were sold at an average price of $21.97, for a total value of $29,417.83. Following the completion of the transaction, the insider owned 65,666 shares in the company, valued at approximately $1,442,682.02. This represents a 2.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 6.50% of the company’s stock.

Castle Biosciences Price Performance

NASDAQ:CSTL opened at $22.51 on Thursday. Castle Biosciences, Inc. has a one year low of $14.59 and a one year high of $35.84. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.69 and a current ratio of 6.85. The firm has a market cap of $653.02 million, a price-to-earnings ratio of -64.31 and a beta of 1.13. The firm’s fifty day moving average is $22.19 and its two-hundred day moving average is $19.72.

Castle Biosciences (NASDAQ:CSTL) last posted its quarterly earnings results on Monday, August 4th. The company reported $0.15 EPS for the quarter, beating the consensus estimate of ($0.51) by $0.66. Castle Biosciences had a negative net margin of 2.73% and a positive return on equity of 2.37%. The company had revenue of $86.18 million for the quarter, compared to analyst estimates of $71.53 million. Castle Biosciences has set its FY 2025 guidance at EPS. Research analysts expect that Castle Biosciences, Inc. will post 0.44 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on CSTL shares. Canaccord Genuity Group reissued a “buy” rating and issued a $37.00 price objective on shares of Castle Biosciences in a research note on Tuesday, September 9th. Zacks Research raised shares of Castle Biosciences from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 27th. Wall Street Zen raised shares of Castle Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, August 10th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Castle Biosciences in a report on Wednesday, October 8th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $36.57.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.